Skip to main content
Caplight Logo









Averna Therapeutics

Averna Therapeutics

Private
Watertown, MassachusettsHealthcare & Life Scienceshttps://avernatx.com/

Last Round

Series A

Jun 25, 2024

Total Funding Raised

$82M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Averna Therapeutics is a biotechnology company that develops RNA/lipid nanoparticle-based genomic medicines to durably and safely treat a broad range of diseases, including genetic disorders, cancer, and autoimmune conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

genomic medicinegene therapyredosable gene therapymRNA therapeuticsLNP deliverygenetic disease treatmentbiotech startuppreclinical biotechdrug discoverynext-gen gene therapyviral-vector alternativestherapeutic platformin silico modeling

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Averna Therapeutics Comparables

Compare Averna Therapeutics with similar companies based on industry and business-model similarity.

Averna Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Stylus Medicine
81%
Ensoma
80%
Tessera Therapeutics
79%

Averna Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 25, 2024

Key People

Founding team and executive leadership

Tal Zaks

Chairman And CEO

Executive Team

Averna Therapeutics Investors

Notable investors and investment history

Averna Therapeutics investors
InvestorRounds
Deep InsightSeries A
Innovation EndeavorsSeries A
OrbiMedSeries A, Seed
Invus OpportunitiesSeries A
Arc VenturesSeries A
Delos Capital PartnersSeries A
InvusSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Open roles increased to 28, 2.3x the trailing average.

  • Jul 24, 2026

    Monthly visitors increased 390% MoM, reaching 7.7K.

Averna Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Averna Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Averna Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWatertown, Massachusetts
Employee Range54
Year Founded2022
Last FundingJun 25, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?